A Real-world Study: Analysis of the Efficacy of Antiviral Therapy in CHB Patients Over 30 Years Old, HBV DNA Positive and ALT Normal
Curative Effect Analysis of Antiviral Therapy in CHB Patients Over 30 Years Old With HBV DNA Positive and Normal ALT
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430000
- Tongji Hospital,Wuhan,Hubei
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- CHB patients over 30 years old ;
- HBV DNA >20IU/ml and ALT level ≤40U/L;
- All of them have never received any antiviral treatment(including NAs and interferon-α)。
Exclusion Criteria:
- pregnancy status;
- Patients with compensated/decompensated cirrhosis and liver cancer have been diagnosed by imaging or other indicators;
- HCV, HIV, EB virus/cytomegalovirus infection, schistosomiasis liver disease, drug-induced liver injury, autoimmune hepatitis and alcoholic liver disease;
- Use immunosuppressants ;
- Previous history of liver cancer, organ transplantation and alcoholism (male ≥30 g/d, female ≥20 g/d);
- Insufficient follow-up time and imperfect clinical/laboratory informations;
- Combined with other major diseases.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
NA treatment
NA treated with TDF,ETV OR TMF
|
|
Control group without antiviral treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
48-week HBV DNA negativity rate(%)
Time Frame: 48 weeks
|
HBV DNA negative rate(%) at 48 weeks
|
48 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
48-week ALT normalization rate(%)
Time Frame: 48 weeks
|
ALT normalization rate(%) at 48 weeks
|
48 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Degree of improvement in liver fibrosis
Time Frame: 48 weeks
|
Changes in liver stiffness measurement (LSM) by FibroScan were used to describe changes in patients' liver fibrosis
|
48 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Meifang Han, Doctor, Tongji Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Organizing Pneumonia
- Immune System Diseases
- Infections
- Virus Diseases
- Respiratory Tract Diseases
- Digestive System Diseases
- Lung Diseases
- Bronchial Diseases
- Lung Diseases, Obstructive
- Liver Diseases
- Hepatitis, Viral, Human
- Communicable Diseases
- DNA Virus Infections
- Hepadnaviridae Infections
- Bronchiolitis Obliterans
- Bronchiolitis
- Bronchitis
- Hepatitis
- Graft vs Host Disease
- Bronchiolitis Obliterans Syndrome
- Hepatitis B
Other Study ID Numbers
Other Study ID Numbers
- ALTN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.